Cargando…

Improving the clinical recognition, prognosis, and treatment of melioidosis through epidemiology and clinical findings: The Sabah perspective

INTRODUCTION: Melioidosis is a deadly endemic disease in northern Australia and Southeast Asia, including Sabah, Malaysia, which is caused by the bacterium Burkholderia pseudomallei. It contributes to high fatality rates, mainly due to misdiagnosis leading to the wrong treatment being administered t...

Descripción completa

Detalles Bibliográficos
Autores principales: Hussin, Ainulkhir, Nor Rahim, Mohd Yusof, Dalusim, Frederick, Shahidan, Muhammad Ashraf, Nathan, Sheila, Ibrahim, Nazlina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10602235/
https://www.ncbi.nlm.nih.gov/pubmed/37844130
http://dx.doi.org/10.1371/journal.pntd.0011696
_version_ 1785126354146033664
author Hussin, Ainulkhir
Nor Rahim, Mohd Yusof
Dalusim, Frederick
Shahidan, Muhammad Ashraf
Nathan, Sheila
Ibrahim, Nazlina
author_facet Hussin, Ainulkhir
Nor Rahim, Mohd Yusof
Dalusim, Frederick
Shahidan, Muhammad Ashraf
Nathan, Sheila
Ibrahim, Nazlina
author_sort Hussin, Ainulkhir
collection PubMed
description INTRODUCTION: Melioidosis is a deadly endemic disease in northern Australia and Southeast Asia, including Sabah, Malaysia, which is caused by the bacterium Burkholderia pseudomallei. It contributes to high fatality rates, mainly due to misdiagnosis leading to the wrong treatment being administered to the patients. Local epidemiology and data on clinical features could assist clinicians during diagnosis and treatment. However, these details are still scarce, particularly in Sabah. METHODS: A retrospective study of 246 culture-confirmed melioidosis cases in Queen Elizabeth Hospital, Sabah, Malaysia was performed between 2016 and 2018. The epidemiological data and clinical and laboratory findings were extracted and analysed. RESULTS: The annual incidence of culture-confirmed melioidosis cases was estimated to be 4.97 per 100,000 people. The mean age of the patients was 50±15 years. Males and members of the Kadazan-Dusun ethnic group accounted for the majority of the melioidosis cases. The odds ratio analysis indicated that bacteraemic melioidosis in this region was significantly associated with fever (76%), and patients having at least one underlying illness (43%), including diabetes mellitus (32%). Sixty-eight patients (28%) succumbed to melioidosis. Contrary to what is known regarding factors that promote bacteraemic melioidosis, neither patients with fever nor patients with at least one comorbid disease, including diabetes mellitus, were significantly associated with death from melioidosis. There was no statistically significant difference between patients without comorbidities (24, 27%) and those with at least one comorbid disease (26, 25%), including diabetes mellitus (18, 23%). The odds ratios indicate that melioidosis mortality in this region is related to patients showing respiratory organ-associated symptoms (29%), bacteraemia (30%), and septic shock (47%). Burkholderia pseudomallei isolates in this study were highly susceptible to ceftazidime (100%), imipenem (100%), and trimethoprim-sulfamethoxazole (98%). CONCLUSIONS: Information obtained from this study can be used by clinicians to recognise individuals with the highest risk of acquiring melioidosis, estimate an accurate prognosis, and provide effective treatment for melioidosis patients to reduce death from melioidosis.
format Online
Article
Text
id pubmed-10602235
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-106022352023-10-27 Improving the clinical recognition, prognosis, and treatment of melioidosis through epidemiology and clinical findings: The Sabah perspective Hussin, Ainulkhir Nor Rahim, Mohd Yusof Dalusim, Frederick Shahidan, Muhammad Ashraf Nathan, Sheila Ibrahim, Nazlina PLoS Negl Trop Dis Research Article INTRODUCTION: Melioidosis is a deadly endemic disease in northern Australia and Southeast Asia, including Sabah, Malaysia, which is caused by the bacterium Burkholderia pseudomallei. It contributes to high fatality rates, mainly due to misdiagnosis leading to the wrong treatment being administered to the patients. Local epidemiology and data on clinical features could assist clinicians during diagnosis and treatment. However, these details are still scarce, particularly in Sabah. METHODS: A retrospective study of 246 culture-confirmed melioidosis cases in Queen Elizabeth Hospital, Sabah, Malaysia was performed between 2016 and 2018. The epidemiological data and clinical and laboratory findings were extracted and analysed. RESULTS: The annual incidence of culture-confirmed melioidosis cases was estimated to be 4.97 per 100,000 people. The mean age of the patients was 50±15 years. Males and members of the Kadazan-Dusun ethnic group accounted for the majority of the melioidosis cases. The odds ratio analysis indicated that bacteraemic melioidosis in this region was significantly associated with fever (76%), and patients having at least one underlying illness (43%), including diabetes mellitus (32%). Sixty-eight patients (28%) succumbed to melioidosis. Contrary to what is known regarding factors that promote bacteraemic melioidosis, neither patients with fever nor patients with at least one comorbid disease, including diabetes mellitus, were significantly associated with death from melioidosis. There was no statistically significant difference between patients without comorbidities (24, 27%) and those with at least one comorbid disease (26, 25%), including diabetes mellitus (18, 23%). The odds ratios indicate that melioidosis mortality in this region is related to patients showing respiratory organ-associated symptoms (29%), bacteraemia (30%), and septic shock (47%). Burkholderia pseudomallei isolates in this study were highly susceptible to ceftazidime (100%), imipenem (100%), and trimethoprim-sulfamethoxazole (98%). CONCLUSIONS: Information obtained from this study can be used by clinicians to recognise individuals with the highest risk of acquiring melioidosis, estimate an accurate prognosis, and provide effective treatment for melioidosis patients to reduce death from melioidosis. Public Library of Science 2023-10-16 /pmc/articles/PMC10602235/ /pubmed/37844130 http://dx.doi.org/10.1371/journal.pntd.0011696 Text en © 2023 Hussin et al https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Hussin, Ainulkhir
Nor Rahim, Mohd Yusof
Dalusim, Frederick
Shahidan, Muhammad Ashraf
Nathan, Sheila
Ibrahim, Nazlina
Improving the clinical recognition, prognosis, and treatment of melioidosis through epidemiology and clinical findings: The Sabah perspective
title Improving the clinical recognition, prognosis, and treatment of melioidosis through epidemiology and clinical findings: The Sabah perspective
title_full Improving the clinical recognition, prognosis, and treatment of melioidosis through epidemiology and clinical findings: The Sabah perspective
title_fullStr Improving the clinical recognition, prognosis, and treatment of melioidosis through epidemiology and clinical findings: The Sabah perspective
title_full_unstemmed Improving the clinical recognition, prognosis, and treatment of melioidosis through epidemiology and clinical findings: The Sabah perspective
title_short Improving the clinical recognition, prognosis, and treatment of melioidosis through epidemiology and clinical findings: The Sabah perspective
title_sort improving the clinical recognition, prognosis, and treatment of melioidosis through epidemiology and clinical findings: the sabah perspective
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10602235/
https://www.ncbi.nlm.nih.gov/pubmed/37844130
http://dx.doi.org/10.1371/journal.pntd.0011696
work_keys_str_mv AT hussinainulkhir improvingtheclinicalrecognitionprognosisandtreatmentofmelioidosisthroughepidemiologyandclinicalfindingsthesabahperspective
AT norrahimmohdyusof improvingtheclinicalrecognitionprognosisandtreatmentofmelioidosisthroughepidemiologyandclinicalfindingsthesabahperspective
AT dalusimfrederick improvingtheclinicalrecognitionprognosisandtreatmentofmelioidosisthroughepidemiologyandclinicalfindingsthesabahperspective
AT shahidanmuhammadashraf improvingtheclinicalrecognitionprognosisandtreatmentofmelioidosisthroughepidemiologyandclinicalfindingsthesabahperspective
AT nathansheila improvingtheclinicalrecognitionprognosisandtreatmentofmelioidosisthroughepidemiologyandclinicalfindingsthesabahperspective
AT ibrahimnazlina improvingtheclinicalrecognitionprognosisandtreatmentofmelioidosisthroughepidemiologyandclinicalfindingsthesabahperspective